Atlas Trials

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Clinical trial NCT03872661 · RECRUITING

Trial details

NCT number
NCT03872661
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Lung Cancer Stage III
Start date
2019-03-01
Primary completion
2029-12-31
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.